Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Octubre 2024 - 3:10PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, granted stock options to purchase 52,000
shares of Astria’s common stock on October 1, 2024 under Astria’s
2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock
Incentive Plan is used exclusively for the grant of equity awards
to individuals who were not previously an employee of Astria.
The options were granted as an inducement material to three
employees entering into employment with Astria in accordance with
Nasdaq Listing Rule 5635(c)(4). The options have an exercise price
of $11.43, which is equal to the closing price of Astria’s common
stock on October 1, 2024 (the “Grant Date”), and will vest over a
four-year period, with 25% of shares vesting on the first
anniversary of the employee’s employment start date (which preceded
the Grant Date) and the remaining shares vesting monthly on a
ratable basis over the following 36 months, subject to the
employee’s continued employment with Astria on such vesting dates.
The options are subject to the terms and conditions of the 2022
Inducement Stock Incentive Plan and the terms and conditions of an
award agreement covering the grant.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by
allergic and immunologic diseases. Our lead program, navenibart
(STAR-0215), is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241002054518/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024